(S)-1-sulfanyl-4-(methylthio)but-2-ylcarbamic acid tert-butyl ester | 141437-94-7

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫代羰基化合物
• 英文名称: (S)-1-sulfanyl-4-(methylthio)but-2-ylcarbamic acid tert-butyl ester
• 英文别名: (S)-tert-butyl 1-mercapto-4-(methylthio)butan-2-ylcarbamate；tert-butyl N-[(2S)-4-methylsulfanyl-1-sulfanylbutan-2-yl]carbamate
• CAS: 141437-94-7
• 化学式: C₁₀H₂₁NO₂S₂
• 分子量: 251.414
• InChiKey: CAGCEWKLPDGHAD-QMMMGPOBSA-N

物化性质

• 沸点：
  364.3±37.0 °C(Predicted)
• 密度：
  1.072±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  15
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  64.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (S)-1-sulfanyl-4-(methylthio)but-2-ylcarbamic acid tert-butyl ester 在 甲酸 、 (benzotriazo-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate 、 三乙胺 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 2.83h， 生成 1-(2-((1-(ethoxycarbonyloxy)isobutoxycarbonylmethyl)carbamoyl)-3-phenylpropyldisulfanylmethyl)-3-methylsulfanylpropyl ammonium trifluoroacetate
  参考文献：
  名称：

  用于中枢和周围疼痛治疗的新型口服活性双脑啡肽抑制剂（DENKIs）

  摘要：

  保护脑啡肽是响应伤害性刺激而释放的内源性阿片肽，是缓解急性和神经性疼痛的一种创新方法。这是通过抑制两个膜结合的锌金属肽酶，中性溶酶（NEP，EC 3.4.24.11）和氨基肽酶N（APN，EC 3.4.11.2）来抑制它们的酶促降解而实现的。已经设计出两种酶的选择性和有效抑制剂，称为脑啡肽酶，它们可以显着增加脑啡肽的细胞外浓度和半衰期，从而诱导有效的抗伤害感受作用。先前已经开发了几种双脑啡肽酶抑制剂（DENKIs）的化学家族，但缺乏口服活性。我们在这里报告新前药的设计和合成，衍生自将NEP和APN抑制剂通过具有侧链的二硫键结合的NEP和APN抑制剂共同改善口服生物利用度。在针对中枢和/或外周阿片样物质系统的各种疼痛动物模型中评估了它们的药理特性。考虑到它在急性和神经性疼痛中的功效，这些新的DENKI之一，选择19 - IIIa进行临床开发。

  DOI：

  10.1021/jm500602h
• 作为产物：
  描述：

  在 甲醇 、 sodium tetrahydroborate 、 三乙胺 、 sodium hydroxide 作用下， 以 四氢呋喃 、 氯仿 、 N,N-二甲基甲酰胺 为溶剂， 生成 (S)-1-sulfanyl-4-(methylthio)but-2-ylcarbamic acid tert-butyl ester
  参考文献：
  名称：

  用于中枢和周围疼痛治疗的新型口服活性双脑啡肽抑制剂（DENKIs）

  摘要：

  保护脑啡肽是响应伤害性刺激而释放的内源性阿片肽，是缓解急性和神经性疼痛的一种创新方法。这是通过抑制两个膜结合的锌金属肽酶，中性溶酶（NEP，EC 3.4.24.11）和氨基肽酶N（APN，EC 3.4.11.2）来抑制它们的酶促降解而实现的。已经设计出两种酶的选择性和有效抑制剂，称为脑啡肽酶，它们可以显着增加脑啡肽的细胞外浓度和半衰期，从而诱导有效的抗伤害感受作用。先前已经开发了几种双脑啡肽酶抑制剂（DENKIs）的化学家族，但缺乏口服活性。我们在这里报告新前药的设计和合成，衍生自将NEP和APN抑制剂通过具有侧链的二硫键结合的NEP和APN抑制剂共同改善口服生物利用度。在针对中枢和/或外周阿片样物质系统的各种疼痛动物模型中评估了它们的药理特性。考虑到它在急性和神经性疼痛中的功效，这些新的DENKI之一，选择19 - IIIa进行临床开发。

  DOI：

  10.1021/jm500602h
• 作为试剂：
  描述：

  (S)-1-sulfanyl-4-(methylthio)but-2-ylcarbamic acid tert-butyl ester 、 (S)-BMPA 在 (S)-1-sulfanyl-4-(methylthio)but-2-ylcarbamic acid tert-butyl ester 作用下， 以65.9的产率得到(S)-2-benzyl-3-(((S)-2-(tert-butoxycarbonylamino)-4-(methylthio)butyl)disulfanyl)propanoic acid
  参考文献：
  名称：

  Aminoacid derivatives containing a disulfanyl group in the form of mixed disulfanyl and aminopeptidase N inhibitors

  摘要：

  本发明涉及一种新型化合物，其化学式为(I)：H2N—CH(R1)—CH2—S—S—CH2—CH(R2)—CONH—R5，其中R1为烃链、苯基或苄基基团，被5或6原子杂环取代的亚甲基基团；R2为苯基或苄基基团、5或6原子芳香杂环、被5或6原子杂环取代的亚甲基基团；R5为CH(R3)—COOR4基团，其中R3为氢、OH或OR基团、饱和烃基团、苯基或苄基基团，OR4为亲水性酯基团，或由氮、硫和氧组成的5或6元杂环，其中至少有两个氮原子，该杂环可被烷基C1-C6、苯基或苄基基团取代。本发明还公开了将该化合物用作药物的用途、包括该化合物的制药组合物、制药可接受的辅料、与至少一种大麻素衍生物结合使用以增强该化合物的镇痛和抗抑郁作用以及/或吗啡或其衍生物的用途。

  公开号：

  US08247608B2

文献信息

• AMINOACID DERIVATIVES CONTAINING A DISULFANYL GROUP IN THE FORM OF MIXED DISULFANYL AND AMINOPEPTIDASE N INHIBITORS
  申请人：Roques Bernard

  公开号：US20090012153A1

  公开（公告）日：2009-01-08

  The invention relates to novel compounds of formula (I): H 2 N—CH(R 1 )—CH 2 —S—S—CH 2 —CH(R 2 )—CONH—R 5 , wherein R 1 is a hydrocarbon chain, phenyl or benzyl radical, methylene radical substituted by a 5 or 6 atom heterocycle; R 2 is a phenyl or benzyl radical, a 5 or 6 atom aromatic heterocycle, methylene group substituted by a 5 or 6 atom heterocycle; R 5 is a CH(R 3 )—COOR 4 radical, wherein R 3 is hydrogen, an OH or OR group, a saturated hydrocarbon group, a phenyl or benzyl radical and OR 4 is hydrophile ester, or 5 or 6 membered heterocycle comprising several heteroatoms selected from a group consisting of nitrogen, sulphur and oxygen, with at least two nitrogene atoms, wherein said heterocycle is substitutable by an alkyl C 1 -C 6 , phenyl or benzyl radical. The use of the inventive compounds in the form of drugs, a pharmaceutical composition comprising said compounds, a pharmaceutically acceptable excipient, the use in conjunction of at least one type of cannabinoid derivative for potentiating the analgesic and antidepressant effect of the novel compounds of formula (I) and/or morphine or the derivatives thereof are also disclosed.

  该发明涉及式(I)的新化合物：H2N—CH(R1)—CH2—S—S— —CH(R2)—CONH—R5，其中R1是一个碳氢链、苯基或苯甲基基团，甲基基团被一个5或6原子杂环取代；R2是一个苯基或苯甲基基团，一个5或6原子芳香杂环，甲基基团被一个5或6原子杂环取代；R5是一个CH(R3)—COOR4基团，其中R3是氢、一个OH或OR基团、一个饱和碳氢基团、一个苯基或苯甲基基团，OR4是亲水酯基，或者由氮、硫和氧组成的几个杂原子选自的5或6元杂环，至少有两个氮原子，其中所述杂环可被一个烷基C1-C6、苯基或苯甲基基团取代。该发明化合物的用途包括作为药物、包含所述化合物的药物组合物、药用可接受的赋形剂，以及与至少一种大麻素衍生物联合使用以增强式(I)式新化合物的镇痛和抗抑郁效果和/或吗啡或其衍生物的效果。
• Modulation of disulfide dual ENKephalinase inhibitors (DENKIs) activity by a transient N-protection for pain alleviation by oral route
  作者：Hervé Poras、Elisabeth Bonnard、Marie-Claude Fournié-Zaluski、Bernard P. Roques

  DOI：10.1016/j.ejmech.2015.07.027

  日期：2015.9

  increases their local concentration selectively induced by pain stimuli triggering analgesic responses. With the aim of increasing the orally antinociceptive responses of the previously described disulfide DENKIs (NH3+CH(R1)CH2–S–S–CH2–C(R2R3)CONHCH(R4)COOR5), we designed new pro-drugs, in the same chemical series, with a transient protection of the free amino group by an acyloxyalkyl carbamate, giving rise

  内源性阿片样物质系统主要由两种阿片样物质受体组成，它们由天然的内部效应子脑啡肽（Met-脑啡肽和Leu-脑啡肽）刺激，存在于控制疼痛的不同部位（周围，脊髓，中央）。我们已经证明，通过两种金属肽酶（中性溶酶和中性氨基肽酶）对脑啡肽失活的保护增加了由局部疼痛刺激触发的镇痛反应而选择性诱导的局部浓度。为了增加先前描述的二硫化物DENKIs（NH3+CH（R 1）CH 2 –S–S–CH 2 –C（R 2 R 3）CONHCH（R 4）COOR 5），我们设计了相同化学系列的新前药，并对它们进行了瞬态保护。氨基甲酸酰氧基烷基酯产生的游离氨基，生成（（CH 3）2 CHCO 2 CH（CH 3）OCONHCH（R 1）CH 2 –S–S–CH 2 –C（R 2 R 3）CONHCH（R 4）COOR 5）前药2a – 2g。这些化合物易于从其母体类似物制备，并具有良好的收率。分别对它们进行了操作系统
• Industrial process for the preparation of (5S, 10S)-10-benzyl-16-methyl-11, 14, 18-trioxo-15, 17, 19-trioxa-2,7,8-trithia-12-azahenicosan-5-aminium(E)-3-carboxyacrylate salt
  申请人：PHARMALEADS

  公开号：US10399936B2

  公开（公告）日：2019-09-03

  The present invention relates to an industrial process for the preparation of (5S,10S)-10-benzyl-16-methyl-11,14,18-trioxo-15,17,19-trioxa-2,7,8-trithia-12-azahenicosan-5-aminium (E)-3-carboxyacrylate salt of following formula (I): wherein X is fumarate. This process comprises the following successive key steps: a kinetic resolution, formation of disulfide compound, peptide coupling, and anion exchange reaction to obtain the desired product of formula (I).

  本发明涉及一种制备下式(I)的(5S,10S)-10-苄基-16-甲基-11,14,18-三氧代-15,17,19-三氧杂-2,7,8-三硫杂-12-氮杂蒽-5-氨基(E)-3-羧基丙烯酸酯盐的工业工艺：其中 X 为富马酸盐。该工艺包括以下连续的关键步骤：动力学解析、二硫化物的形成、肽偶联和阴离子交换反应，以获得所需的式 (I) 产物。
• Mixed-inhibitor-prodrug as a new approach toward systemically active inhibitors of enkephalin-degrading enzymes
  作者：Marie Claude Fournie-Zaluski、Pascal Coric、Serge Turcaud、Evelyne Lucas、Florence Noble、Raphael Maldonado、Bernard P. Roques

  DOI：10.1021/jm00091a016

  日期：1992.6

  In order to evaluate the possible advantages of potentiating the effects of the endogenous enkephalins, to obtain analgesia without the serious drawbacks of morphine, it was essential to design systemically active compounds which inhibit the two metabolizing enzymes, aminopeptidase N (APN) and neutral endopeptidase 24.11 (NEP). A new concept combining the idea of "prodrug" and "mixed inhibitor" was therefore developed. Given the high efficiency of beta-mercaptoalkylamines as APN inhibitors and of N-(mercaptoacyl) amino acids as NEP inhibitors, compounds associating these molecules through disulfide or thioester bonds, which are known to increase lipophilicity and to favor passage across the blood-brain barrier, have been synthesized. An HPLC study indicated that the disulfide bridge was resistant to serum enzymes but was cleaved by brain membrane homogenates, suggesting that the active inhibitors were released in the central nervous system. The validity of the approach was verified by the efficient antinociceptive responses obtained in the hot plate test in mice after iv administration of disulfide-containing inhibitors (ED50s of from 4 to 26 mg/kg on the jump latency time). The analgesic potencies of the "mixed inhibitor-prodrug" RB 101 [H2NCH(CH2CH2SCH3)CH2SSCH2CH(CH2Ph)CONHCH(CH2Ph)COOCH2Ph] after iv administration were three times greater than those of a similar combined dose of its two constitutive moieties. The separation of the two diastereoisomers constituting RB 101 showed that the analgesia has a stereochemical dependence, the (S,S,S)-isomer being more active than the (S,R,S)-isomer. Furthermore, in the tail flick test in the rat, RB 101 gave 38% analgesia at a dose of 80 mg/kg. Due to its high efficiency and its longer pharmacological effect, RB 101 was selected for a complete study of its analgesic properties.
• Potent and systemically active aminopeptidase N inhibitors designed from active-site investigation
  作者：Marie Claude Fournie-Zaluski、Pascale Coric、Serge Turcaud、Luce Bruetschy、Evelyne Lucas、Florence Noble、Bernard P. Roques

  DOI：10.1021/jm00085a013

  日期：1992.4

  Derivatives of amino acids bearing various zinc-coordinating moieties (SH, COOH, CONHOH, and PO3H2) were synthesized and tested for their ability to inhibit aminopeptidase N (APN). Among them, beta-amino thiols were found to be the most efficient with IC50's in the 11-50 nM range. These results suggest that the S1 subsite of APN is a deep but not very large hydrophobic pocket, optimally fitting side chains of moderate bulk endowed with some degree of freedom. The iv administration of the inhibitors, alone, did not induce antinociceptive responses on the hot plate test in mice. However, in presence of 10 mg/kg acetorphan, a prodrug of the neutral endopeptidase inhibitor thiorphan, these compounds gave a large increase in the jump latency time with ED50's of 2 and 2.4 mg/kg for the disulfides of methioninethiol [H2NCH(CH2CH2SCH3)CH2S]2 and S-oxomethioninethiol [H2NCH(CH2CH2S(O)CH3)CH2S]2, respectively. These results show that the disulfide forms of beta-amino thiols are efficient prodrugs of aminopeptidase N inhibitors capable of crossing the blood-brain barrier.